Authors: H Horinouchi, P Taniere, Z Xu, DH Enrico, TJ Kim, H Kanemura, S Savic Prince, Y Zohar, MS Hsieh, TC Hsia, S Viteri, HN Jaafar, E Dawoud, CH Andrade Teixeira, BB Motke, A Magliocco, A Lind, PJ Ansell, R Thiébaut, C Hader
Journal: Annals of Oncology, Volume 36, S1099
Publisher: Elsevier
Date: September 2025
Background
In the LUMINOSITY study (NCT03539536), telisotuzumab vedotin, a c-Met (MET) protein-directed ADC, showed promising antitumor activity in pts with NSQ NSCLC with c-Met OE. We present results from the METRIX study, which evaluated RW prevalence of c-Met OE across geographies, pt ethnicities, and pt characteristics, and associations with key oncogenic driver mutations. The reproducibility of c-Met testing in the RW setting and concordance between local/central labs was assessed.